Angiogenesis and current antiangiogenic strategies for the treatment of cancer

Journal of Vascular and Interventional Radiology

Volumn 21, Issue 12, 2010, Pages 1791-1805

  Oklu, Rahmi ^a   Walker, Thomas G ^a   Wicky, Stephan ^a   Hesketh, Robin ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Abbreviations; Basic fibroblast growth factor; BFGF; DLL4; ERK; Extracellular signalregulated kinase; FDA; Food and Drug Administration; HIF; Hypoxia inducible factor; MAPK; Matrix metalloproteinase; Mitogen activated protein kinase; MMP; Notch ligand delta like 4

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOGENESIS MODULATOR; ANGIOGENIC FACTOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; FINGOLIMOD; FLUOROURACIL; PACLITAXEL; PANITUMUMAB; PEGAPTANIB; PIRENZEPINE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; RANIBIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; BREAST METASTASIS; COLORECTAL CANCER; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HYPOXIA; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NEOPLASM; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; STOMACH CARCINOMA;

EID: 78649493936     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2010.08.009     Document Type: Article

References (129)

1. S.P. Herbert, J. Huisken, and T.N. Kim Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation Science 326 2009 294 298
2. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
3. I.J. Fidler, and L.M. Ellis The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 79 1994 185 188
4. T.A. Fregene, P.S. Khanuja, and A.C. Noto Tumor-associated angiogenesis in prostate cancer Anticancer Res 13 1993 2377 2381
5. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 1993 401 409
6. P.S. Craft, and A.L. Harris Clinical prognostic significance of tumour angiogenesis Ann Oncol 5 1994 305 311
7. B.A. Warren, and P. Shubik The growth of the blood supply to melanoma transplants in the hamster cheek pouch Lab Invest 15 1966 464 478
8. R.M. Merwin, and G.H. Algire The role of graft and host vessels in the vascularization of grafts of normal and neoplastic tissue J Natl Cancer Inst 17 1956 23 33
9. G.H. Algire, and R.M. Merwin vascular patterns in tissues and grafts within transparent chambers in mice Angiology 6 1955 311 318
10. I.F. Tannock The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour Br J Cancer 22 1968 258 273
11. I.F. Tannock, and G.G. Steel Tumor growth and cell kinetics in chronically hypoxic animals J Natl Cancer Inst 45 1970 123 133
12. C.M. Goodall, R. Feldman, A.G. Sanders, and P. Shubik Vascular patterns of four transplantable tumors in the hamster (Mesocricetus auratus) Angiology 16 1965 622 625
13. C.M. Goodall, A.G. Sanders, and P. Shubik Studies of vascular patterns in living tumors with a transparent chamber inserted in hamster cheek pouch J Natl Cancer Inst 35 1965 497 521
14. M. Greenblatt, and P. Shubik Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique J Natl Cancer Inst 41 1968 111 124
15. Y. Shing, J. Folkman, R. Sullivan, C. Butterfield, J. Murray, and M. Klagsbrun Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor Science 223 1984 1296 1299 (Pubitemid 14163183)
16. M. Klagsbrun, and S. Soker VEGF/VPF: the angiogenesis factor found? Curr Biol 3 1993 699 702
17. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 1983 983 985
18. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
19. R.S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis 21 2000 505 515
20. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 2008 2039 2049
21. R.H. Adams, and K. Alitalo Molecular regulation of angiogenesis and lymphangiogenesis Nat Rev Mol Cell Biol 8 2007 464 478
22. K. Alitalo, and P. Carmeliet Molecular mechanisms of lymphangiogenesis in health and disease Cancer Cell 1 2002 219 227
23. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat Med 6 2000 389 395
24. P. Carmeliet Angiogenesis in health and disease Nat Med 9 2003 653 660
25. M. Ohta, H. Konno, and T. Tanaka The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer Cancer Lett 192 2003 215 225
26. Y. Yokoyama, D.S. Charnock-Jones, and D. Licence Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma Clin Cancer Res 9 2003 1361 1369
27. H. Kurahara, S. Takao, K. Maemura, H. Shinchi, S. Natsugoe, and T. Aikou Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis Clin Cancer Res 10 2004 8413 8420
28. A. Adini, T. Kornaga, F. Firoozbakht, and L.E. Benjamin Placental growth factor is a survival factor for tumor endothelial cells and macrophages Cancer Res 62 2002 2749 2752
29. P. Carmeliet, V. Ferreira, and G. Breier Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 380 1996 435 439
30. D. Bellomo, J.P. Headrick, and G.U. Silins Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia Circ Res 86 2000 E29 E35
31. F. Zhang, Z. Tang, and X. Hou VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis Proc Natl Acad Sci U S A 106 2009 6152 6157
32. M.J. Karkkainen, P. Haiko, and K. Sainio Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins Nat Immunol 5 2004 74 80
33. P. Carmeliet, L. Moons, and A. Luttun Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat Med 7 2001 575 583
34. T. Odorisio, C. Schietroma, and M.L. Zaccaria Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability J Cell Sci 115 2002 2559 2567
35. T. Makinen, L. Jussila, and T. Veikkola Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 Nat Med 7 2001 199 205
36. R.N. Kaplan, R.D. Riba, and S. Zacharoulis VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 438 2005 820 827
37. D. Serban, J. Leng, and D. Cheresh H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors Circ Res 102 2008 1350 1358
38. S.A. Lang, P. Schachtschneider, and C. Moser Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes Mol Cancer Ther 7 2008 3509 3518
39. S. Grugel, G. Finkenzeller, K. Weindel, B. Barleon, and D. Marme Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells J Biol Chem 270 1995 25915 25919
40. J. Rak, Y. Mitsuhashi, and L. Bayko Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis Cancer Res 55 1995 4575 4580
41. O.V. Volpert, K.M. Dameron, and N. Bouck Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity Oncogene 14 1997 1495 1502
42. J. Rak, Y. Mitsuhashi, and C. Sheehan Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts Cancer Res 60 2000 490 498
43. J.L. Arbiser, M.A. Moses, and C.A. Fernandez Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways Proc Natl Acad Sci U S A 94 1997 861 866
44. V. Zabrenetzky, C.C. Harris, P.S. Steeg, and D.D. Roberts Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines Int J Cancer 59 1994 191 195
45. D. Mukhopadhyay, L. Tsiokas, and V.P. Sukhatme Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression Cancer Res 55 1995 6161 6165
46. C.L. Kanies, J.J. Smith, and C. Kis Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition Mol Cancer Res 6 2008 1124 1136
47. K. Taniguchi, T. Ishizaki, and T. Ayada Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth Cancer Sci 100 2009 1648 1654
48. J.L. Li, R.C. Sainson, and W. Shi Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo Cancer Res 67 2007 11244 11253
49. I. Noguera-Troise, C. Daly, and N.J. Papadopoulos Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis Nature 444 2006 1032 1037
50. J. Ridgway, G. Zhang, and Y. Wu Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis Nature 444 2006 1083 1087
51. S. Indraccolo, S. Minuzzo, and M. Masiero Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy Cancer Res 69 2009 1314 1323
52. J.E. de Larco, and G.J. Todaro Growth factors from murine sarcoma virus-transformed cells Proc Natl Acad Sci U S A 75 1978 4001 4005
53. M. Laiho, J.A. DeCaprio, J.W. Ludlow, D.M. Livingston, and J. Massague Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation Cell 62 1990 175 185
54. R.M. Niles, N.L. Thompson, and F. Fenton Expression of TGF-beta during in vitro differentiation of hamster tracheal epithelial cells In Vitro Cell Dev Biol Anim 30A 1994 256 262
55. E.H. Filvaroff, R. Ebner, and R. Derynck Inhibition of myogenic differentiation in myoblasts expressing a truncated type II TGF-beta receptor Development 120 1994 1085 1095
56. C. Le Roy, P. Leduque, P.M. Dubois, J.M. Saez, and D. Langlois Repression of transforming growth factor beta 1 protein by antisense oligonucleotide- induced increase of adrenal cell differentiated functions J Biol Chem 271 1996 11027 11033
57. M.J. Goumans, G. Valdimarsdottir, S. Itoh, A. Rosendahl, P. Sideras, and P. ten Dijke Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors EMBO J 21 2002 1743 1753
58. N.P. Barbara, J.L. Wrana, and M. Letarte Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily J Biol Chem 274 1999 584 594
59. M.C. Dickson, J.S. Martin, F.M. Cousins, A.B. Kulkarni, S. Karlsson, and R.J. Akhurst Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice Development 121 1995 1845 1854
60. K.A. McAllister, K.M. Grogg, and D.W. Johnson Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 Nat Genet 8 1994 345 351
61. D.Y. Li, L.K. Sorensen, and B.S. Brooke Defective angiogenesis in mice lacking endoglin Science 284 1999 1534 1537
62. R. Derynck, D.V. Goeddel, and A. Ullrich Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors Cancer Res 47 1987 707 712
63. L.I. Gold The role for transforming growth factor-beta (TGF-beta) in human cancer Crit Rev Oncog 10 1999 303 360
64. G. Ferrari, G. Pintucci, G. Seghezzi, K. Hyman, A.C. Galloway, and P. Mignatti VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis Proc Natl Acad Sci U S A 103 2006 17260 17265
65. G. Ferrari, B.D. Cook, V. Terushkin, G. Pintucci, and P. Mignatti Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis J Cell Physiol 219 2009 449 458
66. W. Iwasaki, K. Nagata, and H. Hatanaka Solution structure of midkine, a new heparin-binding growth factor EMBO J 16 1997 6936 6946
67. S. Tessler, P. Rockwell, and D. Hicklin Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors J Biol Chem 269 1994 12456 12461
68. S. Spiegel, and S. Milstien Sphingosine 1-phosphate, a key cell signaling molecule J Biol Chem 277 2002 25851 25854
69. S.S. Chae, J.H. Paik, H. Furneaux, and T. Hla Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference J Clin Invest 114 2004 1082 1089
70. G. Schmid, M. Guba, and I. Ischenko The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1 J Cell Biochem 101 2007 259 270
71. K. Yonesu, Y. Kawase, and T. Inoue Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog Biochem Pharmacol 77 2009 1011 1020
72. K.M. Argraves, B.A. Wilkerson, W.S. Argraves, P.A. Fleming, L.M. Obeid, and C.J. Drake Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis J Biol Chem 279 2004 50580 50590
73. W. Du, N. Takuwa, and K. Yoshioka S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice Cancer Res 70 2010 772 781
74. B. Enholm, K. Paavonen, and A. Ristimaki Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia Oncogene 14 1997 2475 2483
75. V. Poulaki, C.S. Mitsiades, and C. McMullan Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas J Clin Endocrinol Metab 88 2003 5392 5398
76. S. Kobayashi, T. Kishimoto, S. Kamata, M. Otsuka, M. Miyazaki, and H. Ishikura Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis Cancer Sci 98 2007 726 733
77. M. Mazzone, D. Dettori, and R. Leite de Oliveira Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization Cell 136 2009 839 851
78. B.D. Kelly, S.F. Hackett, and K. Hirota Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1 Circ Res 93 2003 1074 1081
79. A.P. Levy, N.S. Levy, and M.A. Goldberg Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein J Biol Chem 271 1996 25492 25497
80. I. Stein, M. Neeman, D. Shweiki, A. Itin, and E. Keshet Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes Mol Cell Biol 15 1995 5363 5368
81. P.S. Yoo, C.A. Sullivan, and S. Kiang Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival Ann Surg Oncol 16 2009 200 207
82. S. Sinha, S. Dutta, K. Datta, A.K. Ghosh, and D. Mukhopadhyay Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia J Biol Chem 284 2009 32610 32618
83. S.E. Bell, M.J. Sanchez, and O. Spasic-Boskovic The RNA binding protein Zfp36l1 is required for normal vascularisation and post-transcriptionally regulates VEGF expression Dev Dyn 235 2006 3144 3155
84. H. Kikuchi, M.S. Pino, M. Zeng, S. Shirasawa, and D.C. Chung Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer Cancer Res 69 2009 8499 8506
85. S.E. Crawford, V. Stellmach, and J.E. Murphy-Ullrich Thrombospondin-1 is a major activator of TGF-beta1 in vivo Cell 93 1998 1159 1170
86. M.S. O'Reilly, L. Holmgren, and Y. Shing Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328
87. M.S. O'Reilly, L. Holmgren, and Y. Shing Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth Cold Spring Harb Symp Quant Biol 59 1994 471 482
88. M.S. O'Reilly, T. Boehm, and Y. Shing Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277 285
89. K.H. Baek, A. Zaslavsky, and R.C. Lynch Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1 Nature 459 2009 1126 1130
90. R.C. Chan, B. Gutierrez, T.E. Ichim, and F. Lin Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma Oncol Rep 22 2009 1197 1203
91. B. Hobson, and J. Denekamp Endothelial proliferation in tumours and normal tissues: continuous labelling studies Br J Cancer 49 1984 405 413
92. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
93. N. Ferrara VEGF as a therapeutic target in cancer Oncology 69 suppl 3 2005 11 16
94. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
95. A. Grothey, and E. Galanis Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat Rev Clin Oncol 6 2009 507 518
96. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N Engl J Med 358 2008 2606 2617
97. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
98. T.A. Ciulla, and P.J. Rosenfeld Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration Curr Opin Ophthalmol 20 2009 158 165
99. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
100. J.G. Christensen A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities Ann Oncol 18 suppl 10 2007 x3 x10
101. G. Tortora, F. Ciardiello, and G. Gasparini Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications Nat Clin Pract Oncol 5 2008 521 530
102. L.M. Ellis Epidermal growth factor receptor in tumor angiogenesis Hematol Oncol Clin North Am 18 2004 1007 1021
103. J.Y. Song, S.W. Lee, J.P. Hong, S.E. Chang, H. Choe, and J. Choi Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells Cancer Lett 283 2009 135 142
104. M. Wu, A. Rivkin, and T. Pham Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer Clin Ther 30 2008 14 30
105. R.S. Heist, and D. Christiani EGFR-targeted therapies in lung cancer: predictors of response and toxicity Pharmacogenomics 10 2009 59 68
106. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
107. J. Baselga, and J. Albanell Mechanism of action of anti-HER2 monoclonal antibodies Ann Oncol 12 suppl 1 2001 S35 S41
108. G. Mariani, A. Fasolo, E. De Benedictis, and L. Gianni Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer Nat Clin Pract Oncol 6 2009 93 104
109. A. Fasolo, and C. Sessa mTOR inhibitors in the treatment of cancer Expert Opin Investig Drugs 17 2008 1717 1734
110. S. Biswas, and T. Eisen Immunotherapeutic strategies in kidney cancerwhen TKIs are not enough Nat Rev Clin Oncol 6 2009 478 487
111. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1994 4082 4085
112. T. Paravar, and D.J. Lee Thalidomide: mechanisms of action Int Rev Immunol 27 2008 111 135
113. R. Dreicer Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors Curr Oncol Rep 9 2007 120 123
114. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
115. J.M. Ebos, C.R. Lee, and R.S. Kerbel Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clin Cancer Res 15 2009 5020 5025
116. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
117. M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
118. A.R. Reynolds, I.R. Hart, and A.R. Watson Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nat Med 15 2009 392 400
119. T.T. Batchelor, A.G. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95
120. N.T. Fernando, M. Koch, and C. Rothrock Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors Clin Cancer Res 14 2008 1529 1539
121. K. Hida, Y. Hida, and D.N. Amin Tumor-associated endothelial cells with cytogenetic abnormalities Cancer Res 64 2004 8249 8255
122. A.J. Mutsaers Metronomic chemotherapy Top Companion Anim Med 24 2009 137 143
123. M. Lohela, M. Bry, T. Tammela, and K. Alitalo VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Curr Opin Cell Biol 21 2009 154 165
124. D.A. Barbie, P. Tamayo, and J.S. Boehm Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 112
125. E. Meylan, A.L. Dooley, and D.M. Feldser Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma Nature 462 2009 104 107
126. P. Carmeliet, and M. Tessier-Lavigne Common mechanisms of nerve and blood vessel wiring Nature 436 2005 193 200
127. M. Meyer, M. Clauss, and A. Lepple-Wienhues A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases EMBO J 18 1999 363 374
128. L.K. Phng, and H. Gerhardt Angiogenesis: a team effort coordinated by notch Dev Cell 16 2009 196 208
129. L.K. Phng, M. Potente, and J.D. Leslie Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis Dev Cell 16 2009 70 82